Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 4. Summary of Efficacy of Imatinib for GIST

Study ID

Imatinib Dose
[length of followup]

No. of Patients, Age,66 Sex

GIST Tumor Characteristics

Outcomes Sought

N

%CR

%PR

%SD

%PD

%NE

Survival/ Other

Phase II

van Oosterom, et al., 20016
with followup in: van Oosterom, et al., 200245

400-1000 mg dose escalation Phase I; 800 mg Phase II
[9-13 mo]

40 pts
53 [29-69]
63% M

36 had CD117-positive GIST and 4 had non-GIST STS per 2001 report; 35 had CD117 GIST and 5 had non-GIST STS per 2002 report

Liver metastases 75%

60% previous chemotherapy; 10% previous XRT

Tumor response-RECIST CT/PET

Toxicity- NCI CTC v2.0

GIST

36

 

53%

47%

11%

 

At minimum followup of 9-13 mo, 81% of GIST patients were still on imatinib

Non-GIST STS

4

   

25%

75%

 

Demetri, 200246
with repeated report in: Dagher 200243 and followup in: Heinrich, 200347

Randomized between 400 and 600 mg
[minimum 9 mo with median 288 dys; Heinrich, et al., report with 19 mo followup with median 594d]

147 pts
54 [18-83]
57% M

All tumors CD117 positive

100% unresectable or metastatic

90% with recurrence at the time of imatinib therapy

Prior therapies:
 98% Surgery
 51% Chemotherapy
 15% Radiotherapy

Mortality: K-M

Tumor response: MRI/CT RECIST

QOL/PM: (ECOG)

Adverse events: CTC 2.0

All

0%

54%

28%

14%

5%

OS at 76 wks = 85%

Median EFS = 17 mo

400 mg dose (73)

0%

49%

32%

16%

3%

600 mg dose (74)

0%

58%

24%

11%

1%

Verweij, 200348

800 mg
[median followup =13+ mo for GIST pts and 2 mo for non-GIST STS pts]

51 (27 GIST 24 STS)
53 [21-75]
67% M

GIST = CD117 positive

All advanced, unresectable or metastatic

Prior therapies:
 88% surgery
 24% radiotherapy
 71% chemotherapy

Tumor response: RECIST

Time to progression

GIST

27

4%

67%

19%

11%

 

GIST with 73% DFS at 1 yr

Non-GIST STS

24

0%

0%

29%

NR

 

Verweij, 200449
with followup in: Zalcberg, 200450 (abstract)

Randomized between Imatinib 400 mg/d vs. Imatinib 800 mg/d (given as 400 mg twice daily)
[median followup 760d]

946

473 @400 mg/d
59 [49-67]
60% M

473@800 mg/d
60 [49-68]
61% M

GIST = CD117 positive

All advanced, unresectable or metastatic

400 mg qd:
 87% surgery
 6% radiotherapy
 33% chemotherapy

800 mg qd:
 83% surgery
 8% radiotherapy
 33% chemotherapy

Progression free survival-KM

Overall survival-KM

Tumor response-CT or MRI RECIST

Toxicity-NCI CTC version 2.0

400 mg/d
(473)

5%

45%

32%

13%

5%

1 yr survival:
 400 mg/d = 85%
 800 mg/d = 85%

2 yr survival:
 400 mg/d = 69%
 800 mg/d = 74%

2 yr PFS:
 400 mg/d = 44%
 800 mg/d = 50% (p = 0.026)

220 of the 473 patients on 400 mg/d have PD and 143 have crossed to 800 mg/d; 26% progression free at 1 year with med TTP 78d compared to 203d prior to crossover; toxicity required dose reduction in 31%; interpretation is that crossover is feasible

800  mg/d
(473)

6%

48%

32%

9%

5%

Casali, 200451
(abstract)

Unk dose
[9 mo]

135
65 [unk]
70% M
(129 patients evaluable)

GIST = CD117 positive

All advanced, unresectable or metastatic

Tumor response- RECIST

129

 

44%
(PR + CR)

     

PFS > 70%

Phase III

Blay, 200452
(abstract)

Unk doses

One year of imatinib then randomized between continuous imatinib vs. interruption of imatinib until progression then restart
[6 mo]

159
Age unk
61% M

Advanced GIST expressing a KIT or PDGFRa mutation

Progression free survival

Tumor response

159

10%

42%

36%

6%

6%

Reintroduction of imatinib yielded tumor control in all 5 who progressed

Randomized to continuous
N = 23

0%

Randomized to intermittent
N = 23

21%

Rankin, 200453 and Patel 200354
(abstracts)

Randomized between Imatinib 400 mg/d vs Imatinib 800 mg/d (given as 400 mg twice daily)
[median 768d, range 70-1029d]

746
Age unk
Gender unk

Metastatic GIST

Progression free survival

Overall survival-KM

Tumor response

400 mg

         

2 yr survival:
 400 mg/d = 78% (CI 73-82%)
 800 mg/d = 73% (CI 68-77%)

2 yr PFS:
 400 mg/d = 50% (CI 45-55%)
 800 mg/d = 53% (CI 47-58%)

164 patients at 400 mg/d have progressed and 88 164 crossed over to 800 mg/d, with 7% PR and 29% SD after crossover; after crossover, median PPS = 4 mo and median OS = 19 mo

Abbreviations: CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable; RECIST and CR/PR/SD/PD – go to Table 2; NCI = National Cancer Institute; CTC = Common Toxicity Criteria; K-M = Kaplan-Meier; QOL = Quality of life; PM = performance measure; ECOG = Eastern Oncology Cooperative Group performance status scale; OS = overall survival; EFS = event-free survival, go to Table 2; STS = soft-tissue sarcoma; NR = not reported; DFS = Disease free survival, go to Table 2; Unk = unknown; PFS = progression-free survival, go to Table 2; CI = 95% confidence interval

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care